Evolus, Inc. (EOLS) Stock Analysis and Metrics

Evolus

NASDAQ: EOLS

$5.99 ▼ 0.00 (-0.08%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap393.73 Mn

P/E-9.07

P/S1.30

Div. Yield0.00

Total Debt (Qtr)156.41 Mn

Revenue Growth (1y) (Qtr)6.74

Add ratio to table…

About

Evolus, Inc. is a global performance beauty company that delivers breakthrough products with a customer centric approach. The company focuses on the cash pay aesthetic market where consumers purchase medical products out of pocket. Its customers are licensed aesthetic practitioners who administer the products. By pursuing an aesthetic only non reimbursed product strategy Evolus avoids the regulatory burdens associated with third party payor reimbursed therapies and gains flexibility in marketing and pricing.

Evolus generates revenue primarily from the sale of its two commercial product lines Jeuveau and Evolysse. Jeuveau is a purified botulinum toxin type A neurotoxin sold to aesthetic practitioners for the temporary improvement of frown lines. Evolysse is a collection of injectable hyaluronic acid gels used to treat wrinkles folds mid face volume lip fullness and infraorbital hollows. Revenue is driven by direct product sales co branded marketing programs promotional events pricing strategies and a customer loyalty program that encourages repeat purchases.

The company operates through the following segments.

• Jeuveau: This segment provides a proprietary 900 kilodalton purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

• Evolysse: This segment offers a collection of injectable hyaluronic acid gels utilizing first generation cold technology including products such as Evolysse Form Evolysse Smooth Evolysse Sculpt and Evolysse Lips for treatment of wrinkles folds mid face volume lip fullness and infraorbital hollow correction.

Evolus holds a competitive position in the medical aesthetics industry where it faces established rivals such as Abbvie Galderma Merz Revance Hugel and Medytox in the neurotoxin market and Abbvie Galderma Merz Revance Prollenium Medical Technologies and Obagi in the dermal filler market. The company differentiates itself by concentrating on the largest and fastest growing aesthetic segments neurotoxins and hyaluronic acid gels by maintaining an aesthetic only strategy that reduces regulatory complexity and by leveraging a differentiated digital platform that streamlines account opening personalizes purchasing and scales co branded marketing efforts. Additionally Evolus benefits from comprehensive clinical data from its TRANSPARENCY program and from reliable manufacturing partnerships with Daewoong for Jeuveau and Symatese for Evolysse.

The company serves licensed aesthetic practitioners including medical spas dermatology clinics and plastic surgery practices that are authorized to administer its injectable products.

Investment Thesis

▲ Bull case

Evolus, Inc. is demonstrating strong foundational strength through its Performance Beauty platform, which integrates digital tools, AI-driven insights, and customer engagement to create a scalable and efficient commercial model. The company reported a 7% year-over-year increase in global net revenue to $73.1 million in Q1 FY26, with Jeuveau delivering $66.4 million and Evolisse contributing $6.7 million. Despite seasonal headwinds from prior-year revenue deferrals, underlying demand remains intact, with unit growth in both U.S. and international Jeuveau markets. The company’s adjusted EBITDA turned positive at $0.6 million in Q1 FY26 compared to a $5.5 million loss in the prior-year period, driven by revenue growth and improved cost efficiency from structural actions taken in 2025. This profitability in the seasonally weakest quarter validates the durability of its operating model and supports confidence in achieving full-year adjusted EBITDA profitability and double-digit revenue growth in 2026, as reiterated in guidance.
The upcoming mid-May launch of Estyme in Europe represents a significant, underappreciated catalyst that expands Evolus’ addressable market and leverages its existing commercial infrastructure. Estyme includes four injectable HA gels—Smooth, Form, Lips, and Sculpt—with Sculpt being the flagship mid-face volumizing product, addressing a high-demand treatment area. The launch follows successful CE Mark certification under the stringent EU MDR, validating safety, efficacy, and quality. By introducing a full neurotoxin (Nuceiva) and HA gel portfolio in Europe, Evolus differentiates itself from competitors offering only one product type. The company plans to leverage insights from the European launch to inform its U.S. strategy for Evolisse Sculpt, which anticipates FDA approval in Q4 FY26. This sequential rollout reduces risk and enhances commercial precision, positioning Evolus to capture share in a growing international aesthetic market while building toward its long-term goal of international revenues contributing roughly 15% of total revenue.
Evolus’ digital ecosystem and AI integration are creating tangible operational efficiencies that are not fully reflected in current financial metrics but are driving sustainable margin expansion. The unified data platform connects practice engagement, product ordering, consumer acquisition, and loyalty programs into a continuous feedback loop that fuels AI-driven targeting, improved field productivity, and faster decision-making. Over the past year, the company embedded AI into core business areas, enabling real-time insights for customer targeting and conversion. This integration supports portfolio bundling strategies, which increase share of wallet without eroding margins, as confirmed by CFO Tatjana Mitchell, who noted the rebate program maintains healthy margin rates. With Evolus Rewards approaching 1.5 million members (up 27% YoY) and redemptions exceeding 255,000 in Q1, the company is deepening customer retention and repeat utilization. These capabilities allow Evolus to scale efficiently, translating into operating leverage and profitability that compound over time, especially as international expansion and new product launches scale the business without proportional cost increases.

Evolus, Inc. is demonstrating strong foundational strength through its Performance Beauty platform, which integrates digital tools, AI-driven insights, and customer engagement to create a scalable and efficient commercial model. The company reported a 7% year-over-year increase in global net revenue to $73.1 million in Q1 FY26, with Jeuveau delivering $66.4 million and Evolisse contributing $6.7 million. Despite seasonal headwinds from prior-year revenue deferrals, underlying demand remains intact, with unit growth in both U.S. and international Jeuveau markets. The company’s adjusted EBITDA turned positive at $0.6 million in Q1 FY26 compared to a $5.5 million loss in the prior-year period, driven by revenue growth and improved cost efficiency from structural actions taken in 2025. This profitability in the seasonally weakest quarter validates the durability of its operating model and supports confidence in achieving full-year adjusted EBITDA profitability and double-digit revenue growth in 2026, as reiterated in guidance.
The upcoming mid-May launch of Estyme in Europe represents a significant, underappreciated catalyst that expands Evolus’ addressable market and leverages its existing commercial infrastructure. Estyme includes four injectable HA gels—Smooth, Form, Lips, and Sculpt—with Sculpt being the flagship mid-face volumizing product, addressing a high-demand treatment area. The launch follows successful CE Mark certification under the stringent EU MDR, validating safety, efficacy, and quality. By introducing a full neurotoxin (Nuceiva) and HA gel portfolio in Europe, Evolus differentiates itself from competitors offering only one product type. The company plans to leverage insights from the European launch to inform its U.S. strategy for Evolisse Sculpt, which anticipates FDA approval in Q4 FY26. This sequential rollout reduces risk and enhances commercial precision, positioning Evolus to capture share in a growing international aesthetic market while building toward its long-term goal of international revenues contributing roughly 15% of total revenue.
Evolus’ digital ecosystem and AI integration are creating tangible operational efficiencies that are not fully reflected in current financial metrics but are driving sustainable margin expansion. The unified data platform connects practice engagement, product ordering, consumer acquisition, and loyalty programs into a continuous feedback loop that fuels AI-driven targeting, improved field productivity, and faster decision-making. Over the past year, the company embedded AI into core business areas, enabling real-time insights for customer targeting and conversion. This integration supports portfolio bundling strategies, which increase share of wallet without eroding margins, as confirmed by CFO Tatjana Mitchell, who noted the rebate program maintains healthy margin rates. With Evolus Rewards approaching 1.5 million members (up 27% YoY) and redemptions exceeding 255,000 in Q1, the company is deepening customer retention and repeat utilization. These capabilities allow Evolus to scale efficiently, translating into operating leverage and profitability that compound over time, especially as international expansion and new product launches scale the business without proportional cost increases.

▼ Bear case

Evolus, Inc. faces significant near-term headwinds from external regulatory and macroeconomic pressures that management may be underestimating, particularly the 15% tariff on certain pharmaceutical products from South Korea, including Jeuveau, effective September 29, 2026. Although the company states it is evaluating mitigation options and plans to build U.S. inventory leveraging Jeuveau’s three-year shelf life, the tariff poses a material risk to gross margins if not fully offset. Reported gross margin was 67% in Q1 FY26, with adjusted gross margin at 68%, leaving little room for error. Any failure to mitigate the tariff could directly erode profitability, especially as the company relies on Jeuveau for over 90% of its revenue. Furthermore, the company’s assertion that the tariff does not impact its 2026 outlook assumes successful mitigation, but no concrete solution has been disclosed, creating uncertainty around long-term cost structure and pricing power in a competitive market where alternatives like Botox and Dysport are not subject to the same tariff.
The filler market recovery remains fragile and uneven, with Evolus potentially overestimating the pace of rebound and the success of its Evolisse launch amid persistent competitive disadvantages. While management noted improving sentiment and rising clinician interest in HAs, the U.S. filler market was flat to slightly down in Q1 FY26, and Evolisse’s $6.7 million in revenue represents early-stage traction. Competitors have decade-long market presence, established clinician relationships, and full product lines, creating high switching costs. Evolus’ reliance on training and bundling to drive adoption may not overcome entrenched preferences, especially as the company does not compete in the mid-face segment—Sculp’s anticipated Q4 FY26 approval is critical but still months away. Without Sculpt, Evolisse’s portfolio lacks completeness, limiting its ability to counter competitive bundles. Additionally, the company’s portfolio growth rebate, while structured to maintain margins, may require deeper discounts over time to gain share, posing a risk to profitability if market reversion to growth does not materialize as expected.
International expansion, while promising, introduces execution and regulatory risks that could delay or diminish the expected benefits of the Estyme launch in Europe. The launch depends on Symatese for regulatory approval and supply chain support in the U.S., creating a single-point dependency for Evolisse Sculpt and related HA gels. Any delay in Symatese’s ability to secure or maintain regulatory approvals—whether in the U.S. or Europe—could disrupt product availability and launch timelines. Furthermore, while the company cites strong growth in mature markets like the U.K., it provides limited visibility into performance across other European countries, raising concerns about uneven adoption. The Estyme launch, though supported by CE Mark certification, faces challenges in gaining formulary access, clinician education, and reimbursement pathways in fragmented European healthcare systems. Without clear data on early traction or market acceptance, the assumption that Europe will meaningfully contribute to revenue growth in FY26 remains speculative, especially given the launch occurs mid-quarter and initial stocking orders are expected to be modest.

Evolus, Inc. faces significant near-term headwinds from external regulatory and macroeconomic pressures that management may be underestimating, particularly the 15% tariff on certain pharmaceutical products from South Korea, including Jeuveau, effective September 29, 2026. Although the company states it is evaluating mitigation options and plans to build U.S. inventory leveraging Jeuveau’s three-year shelf life, the tariff poses a material risk to gross margins if not fully offset. Reported gross margin was 67% in Q1 FY26, with adjusted gross margin at 68%, leaving little room for error. Any failure to mitigate the tariff could directly erode profitability, especially as the company relies on Jeuveau for over 90% of its revenue. Furthermore, the company’s assertion that the tariff does not impact its 2026 outlook assumes successful mitigation, but no concrete solution has been disclosed, creating uncertainty around long-term cost structure and pricing power in a competitive market where alternatives like Botox and Dysport are not subject to the same tariff.
The filler market recovery remains fragile and uneven, with Evolus potentially overestimating the pace of rebound and the success of its Evolisse launch amid persistent competitive disadvantages. While management noted improving sentiment and rising clinician interest in HAs, the U.S. filler market was flat to slightly down in Q1 FY26, and Evolisse’s $6.7 million in revenue represents early-stage traction. Competitors have decade-long market presence, established clinician relationships, and full product lines, creating high switching costs. Evolus’ reliance on training and bundling to drive adoption may not overcome entrenched preferences, especially as the company does not compete in the mid-face segment—Sculp’s anticipated Q4 FY26 approval is critical but still months away. Without Sculpt, Evolisse’s portfolio lacks completeness, limiting its ability to counter competitive bundles. Additionally, the company’s portfolio growth rebate, while structured to maintain margins, may require deeper discounts over time to gain share, posing a risk to profitability if market reversion to growth does not materialize as expected.
International expansion, while promising, introduces execution and regulatory risks that could delay or diminish the expected benefits of the Estyme launch in Europe. The launch depends on Symatese for regulatory approval and supply chain support in the U.S., creating a single-point dependency for Evolisse Sculpt and related HA gels. Any delay in Symatese’s ability to secure or maintain regulatory approvals—whether in the U.S. or Europe—could disrupt product availability and launch timelines. Furthermore, while the company cites strong growth in mature markets like the U.K., it provides limited visibility into performance across other European countries, raising concerns about uneven adoption. The Estyme launch, though supported by CE Mark certification, faces challenges in gaining formulary access, clinician education, and reimbursement pathways in fragmented European healthcare systems. Without clear data on early traction or market acceptance, the assumption that Europe will meaningfully contribute to revenue growth in FY26 remains speculative, especially given the launch occurs mid-quarter and initial stocking orders are expected to be modest.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password